Losartan Potassium Tablet, Film Coated
Product Images NDC 71610-466

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-466). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 50 mg (71610 0466 30)

Losartan Potassium 50 mg film-coated tablets label from Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions for 20-25 degrees Celsius, packaging information indicating 30 tablets per unit, and mentions manufacture by Mahobaob Nagar, India. The label also displays a barcode, NDC 71610-0466-30, and typical prescription drug labeling details.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with primary endpoints over 60 months between Atenolol and Losartan Potassium. The graph shows study months on the x-axis and percentage of patients on the y-axis, with Atenolol represented by a dotted line and Losartan Potassium by a solid line, indicating adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over a 66-month study period for Atenolol and Losartan Potassium. The graph shows a lower stroke incidence trend for Losartan Potassium than Atenolol, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

The figure presents a comparative forest plot chart showing Primary Endpoint Events within demographic subgroups for Losartan Potassium and Atenolol. It details event rates, hazard ratios, and confidence intervals for overall results, age, gender, race, ISH, diabetes, and history of cardiovascular disease, separating outcomes for Primary Composite and Stroke (Fatal/Non-Fatal) events.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with events over time between Losartan potassium and placebo groups. The x-axis represents months (0 to 48), and the y-axis shows the percentage of patients with events (0 to 60%). Two lines show that Losartan potassium has a lower event rate compared to placebo, with a risk reduction of 16.1% and a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium showing its molecular arrangement including chlorinated biphenyl, tetrazole ring, and potassium ion components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.